Filing Flows

Filing Flows › Companies › ArriVent BioPharma › Cash flow

ArriVent BioPharma cash flow, quarter by quarter

Latest: Q3 2026 · from the cash-flow statements filed with the SEC

Free cash flow−$40.7M in Q3 2026 · −$153M over twelve months

Operating cash flow−$40.7M
Free cash flow−$40.7M

Analysis

In Q3 2026, ArriVent BioPharma generated −$40.7M of operating cash flow. That is $4.9M less than in Q3 2025 (−$35.8M).

Over the twelve months to Sep 30, 2026, operating cash flow was −$153M; the largest uses were operating cash flow ($153M), other investing ($82.2M), other financing ($17K); besides operations, cash came from shares issued ($236M); the cash balance rose by $911K.

Operating cash flow was −$40.7M against net income of −$40.3M. The largest differences: stock-based pay +$6.9M, accrued liabilities −$4.6M, prepaid and other assets −$2.4M.

Free cash flow

ArriVent BioPharma: free cash flow by quarterArriVent BioPharma: free cash flow by quarter−$16.2MQ4 2024−$68.0MQ1 2025−$26.1MQ2 2025−$35.8MQ3 2025−$30.7MQ4 2025−$41.9MQ1 2026−$39.6MQ2 2026−$40.7MQ3 2026
Operating cash flow less capital spending.
ArriVent BioPharma: operating cash flow against capital spendingArriVent BioPharma: operating cash flow against capital spendingOperating cash flowCapital spending−$16.2M$0Q4 2024−$68.0M$0Q1 2025−$26.1M$0Q2 2025−$35.8M$0Q3 2025−$30.7M$0Q4 2025−$41.9M$0Q1 2026−$39.6M$0Q2 2026−$40.7M$0Q3 2026
Latest (Q3 2026): Operating cash flow −$40.7M, Capital spending $0.

Capital allocation, year by year

ArriVent BioPharma: where the cash came from (up) and went (down), by fiscal yearArriVent BioPharma: where the cash came from (up) and went (down), by fiscal yearOperating cash flowShares issuedFY2023: Operating cash flow −$55.8MFY2023: Shares issued $45.3M$45.3MFY2023FY2024: Operating cash flow −$70.2MFY2024: Shares issued $187M$187MFY2024FY2025: Operating cash flow −$161MFY2025: Shares issued $203M$203MFY2025
Over these 3 years operating cash flow totalled −$287M; the largest uses were operating cash flow ($287M). Cash-flow statements as filed.

Where the cash came from and went

ArriVent BioPharma: sources (+) and uses (−) of cash, Q3 2026ArriVent BioPharma: sources (+) and uses (−) of cash, Q3 2026Other investing−$60.7MShares issued$60.3MCash drawn (+) / kept (−)$41.1MOperating cash flow−$40.7M
ArriVent BioPharma: sources (+) and uses (−) of cash, TTM to Q3 2026ArriVent BioPharma: sources (+) and uses (−) of cash, TTM to Q3 2026Shares issued$236MOperating cash flow−$153MOther investing−$82.2MCash drawn (+) / kept (−)−$911KOther financing−$17K

From profit to cash

ArriVent BioPharma: net income to operating cash flow, Q3 2026ArriVent BioPharma: net income to operating cash flow, Q3 2026Net income−$40.3MDepreciation & amortization−$653KStock-based pay$6.9MPayables$400KAccrued liabilities−$4.6MPrepaid and other assets−$2.4MOperating cash flow−$40.7M
Non-cash charges are added back; money tied up in receivables or inventory is subtracted.

Every quarter

QuarterOperating cash flowShares issuedCash drawn (+) / kept (−)Free cash flow
Q3 2026−$40.7M$60.3M$41.1M−$40.7M
Q2 2026−$39.6M$86.1M−$92.6M−$39.6M
Q1 2026−$41.9M$54.9M−$16.6M−$41.9M
Q4 2025−$30.7M$34.7M$67.1M−$30.7M
Q3 2025−$35.8M$86.2M$93K−$35.8M
Q2 2025−$26.1M$75.4M−$62.9M−$26.1M
Q1 2025−$68.0M$6.8M$24.4M−$68.0M
Q4 2024−$16.2M$55K$209M−$16.2M

ArriVent BioPharma: income statement and cash flow

ArriVent BioPharma, Q3 2026: revenue $5.0M, operating margin -867.5%. The chart follows the revenue to costs, profit and cash.

ArriVent BioPharma: every quarter, Q/Q and Y/Y → Open in the app

Read automatically from the company’s XBRL cash-flow statements; quarterly figures for the fourth quarter are the year less the first three. Errors are possible. Not investment advice.